Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating BP1002 in patients with refractory or relapsed acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BP1002

Snippet

Sponsor: Bio-Path Holdings, Inc. | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Status: RECRUITING